This drug entry is a stub and has not been fully annotated. It was added on August 25, 2016 and is scheduled to be annotated soon.

Identification
NameAclarubicin
Accession NumberDB11617
TypeSmall Molecule
GroupsInvestigational
DescriptionNot Available
Structure
Thumb
Synonyms
Aclacinomycin A
External IDs NSC-208734
Product Ingredients
IngredientUNIICASInChI KeyDetails
Aclarubicin hydrochloride501948RI66 75443-99-1KUSMIBXCRZTVML-PCCPLWKKSA-NDetails
ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII74KXF8I502
CAS number57576-44-0
WeightAverage: 811.878
Monoisotopic: 811.341520011
Chemical FormulaC42H53NO15
InChI KeyUSZYSDMBJDPRIF-SVEJIMAYSA-N
InChI
InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+/m0/s1
IUPAC Name
methyl (1R,2R,4S)-4-{[(2R,4S,5S,6S)-4-(dimethylamino)-5-{[(2S,4S,5S,6S)-4-hydroxy-6-methyl-5-{[(2R,6S)-6-methyl-5-oxooxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate
SMILES
CC[C@@]1(O)C[[email protected]](O[[email protected]]2C[C@@H]([[email protected]](O[[email protected]]3C[[email protected]](O)[[email protected]](O[[email protected]]4CCC(=O)[[email protected]](C)O4)[[email protected]](C)O3)[[email protected]](C)O2)N(C)C)C2=C(O)C3=C(C=C2[[email protected]]1C(=O)OC)C(=O)C1=C(C(O)=CC=C1)C3=O
Pharmacology
IndicationNot yet annotated
PharmacodynamicsNot yet annotated
Mechanism of actionNot yet annotated
Related Articles
Interactions
Drug Interactions
DrugInteractionDrug group
AceclofenacAceclofenac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Aclarubicin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
Alendronic acidAclarubicin may increase the hypocalcemic activities of Alendronic acid.Approved
AmdinocillinThe serum concentration of Aclarubicin can be decreased when it is combined with Amdinocillin.Withdrawn
AmoxicillinThe serum concentration of Aclarubicin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Aclarubicin.Approved, Investigational
AmpicillinThe serum concentration of Aclarubicin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AntipyrineAntipyrine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
ApremilastApremilast may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
Atracurium besylateAclarubicin may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Aclarubicin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Aclarubicin can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Aclarubicin can be decreased when it is combined with Bacampicillin.Approved
BalsalazideBalsalazide may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
BenoxaprofenBenoxaprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Aclarubicin can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzylpenicillinThe serum concentration of Aclarubicin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of Aclarubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Aclarubicin.Approved, Investigational
Botulinum Toxin Type AAclarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BAclarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BromfenacBromfenac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Aclarubicin.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Aclarubicin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Aclarubicin.Approved
CarbenicillinThe serum concentration of Aclarubicin can be decreased when it is combined with Carbenicillin.Approved
CarboplatinAclarubicin may increase the ototoxic activities of Carboplatin.Approved
CarprofenCarprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Vet Approved
Cisatracurium besylateAclarubicin may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Aclarubicin.Approved
ClodronateAclarubicin may increase the hypocalcemic activities of Clodronate.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
CloxacillinThe serum concentration of Aclarubicin can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ColistimethateAclarubicin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CyclacillinThe serum concentration of Aclarubicin can be decreased when it is combined with Cyclacillin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Aclarubicin.Approved, Investigational
CyclosporineAclarubicin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
DecamethoniumAclarubicin may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Aclarubicin.Approved
DiclofenacDiclofenac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of Aclarubicin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DiflunisalDiflunisal may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Aclarubicin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Aclarubicin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Aclarubicin.Approved, Investigational
Domoic AcidAclarubicin may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chlorideAclarubicin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DroxicamDroxicam may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
EpirizoleEpirizole may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Aclarubicin.Approved
EtanerceptEtanercept may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
Etidronic acidAclarubicin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
EtoricoxibEtoricoxib may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
FenbufenFenbufen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
FloctafenineFloctafenine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of Aclarubicin can be decreased when it is combined with Flucloxacillin.Approved
FlurbiprofenFlurbiprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Aclarubicin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Aclarubicin.Approved, Vet Approved
Gallamine TriethiodideAclarubicin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
HMPL-004HMPL-004 may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
IbandronateAclarubicin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
IndomethacinIndomethacin may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Withdrawn
IsoxicamIsoxicam may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
LeflunomideLeflunomide may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
LornoxicamLornoxicam may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
LoxoprofenLoxoprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
LumiracoxibLumiracoxib may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of Aclarubicin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
MecamylamineAclarubicin may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Withdrawn
MeticillinThe serum concentration of Aclarubicin can be decreased when it is combined with Meticillin.Approved
MetocurineAclarubicin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideAclarubicin may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MezlocillinThe serum concentration of Aclarubicin can be decreased when it is combined with Mezlocillin.Approved
MivacuriumAclarubicin may increase the respiratory depressant activities of Mivacurium.Approved
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
NafcillinThe serum concentration of Aclarubicin can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Vet Approved
NCX 4016NCX 4016 may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
NepafenacNepafenac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
Niflumic AcidNiflumic Acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Withdrawn
OleandrinAnvirzel may decrease the cardiotoxic activities of Aclarubicin.Experimental
OlopatadineOlopatadine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
OuabainOuabain may decrease the cardiotoxic activities of Aclarubicin.Approved
OxacillinThe serum concentration of Aclarubicin can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Aclarubicin.Approved, Vet Approved
PamidronateAclarubicin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumAclarubicin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
PhenoxymethylpenicillinThe serum concentration of Aclarubicin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
PipecuroniumAclarubicin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Aclarubicin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Aclarubicin.Experimental
PirfenidonePirfenidone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
PiroxicamPiroxicam may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
PivampicillinThe serum concentration of Aclarubicin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Aclarubicin can be decreased when it is combined with Pivmecillinam.Approved
Procaine benzylpenicillinThe serum concentration of Aclarubicin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
PropacetamolPropacetamol may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
PTC299PTC299 may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
RapacuroniumAclarubicin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental, Investigational
RisedronateAclarubicin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumAclarubicin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational, Withdrawn
SalicylamideSalicylamide may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
SRT501SRT501 may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
SuccinylcholineAclarubicin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of Aclarubicin can be decreased when it is combined with Sulbactam.Approved
SulfasalazineSulfasalazine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
SuprofenSuprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Withdrawn
TazobactamThe serum concentration of Aclarubicin can be decreased when it is combined with Tazobactam.Approved
Technetium Tc-99m MedronateAclarubicin may increase the hypocalcemic activities of Technetium Tc-99m Medronate.Approved
TenofovirThe serum concentration of Aclarubicin can be increased when it is combined with Tenofovir.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Aclarubicin can be decreased when it is combined with Ticarcillin.Approved, Vet Approved
Tiludronic acidAclarubicin may increase the hypocalcemic activities of Tiludronate.Approved, Vet Approved
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Aclarubicin.Approved
TranilastTranilast may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Aclarubicin.Approved, Investigational
Trisalicylate-cholineTrisalicylate-choline may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
TubocurarineAclarubicin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of Aclarubicin.Approved
VecuroniumAclarubicin may increase the respiratory depressant activities of Vecuronium.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
ZileutonZileuton may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidAclarubicin may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Jensen PB, Jensen PS, Demant EJ, Friche E, Sorensen BS, Sehested M, Wassermann K, Vindelov L, Westergaard O, Hansen HH: Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Cancer Res. 1991 Oct 1;51(19):5093-9. [PubMed:1655244 ]
  2. Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, Nieuwland M, Ovaa H, Rottenberg S, van Tellingen O, Janssen J, Huijgens P, Zwart W, Neefjes J: Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun. 2013;4:1908. doi: 10.1038/ncomms2921. [PubMed:23715267 ]
  3. Pang B, de Jong J, Qiao X, Wessels LF, Neefjes J: Chemical profiling of the genome with anti-cancer drugs defines target specificities. Nat Chem Biol. 2015 Jul;11(7):472-80. doi: 10.1038/nchembio.1811. Epub 2015 May 11. [PubMed:25961671 ]
External Links
ATC CodesL01DB04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingTreatmentCerebroretinal Vasculopathy, Hereditary / Vasculopathy, Retinal, With Cerebral Leukodystrophy1
2RecruitingTreatmentAcute Myeloid Leukaemias (AML)1
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.218 mg/mLALOGPS
logP2.79ALOGPS
logP3.98ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)7.47ChemAxon
pKa (Strongest Basic)8.64ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count15ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area217.05 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity203.87 m3·mol-1ChemAxon
Polarizability84.31 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as anthracyclines. These are polyketides containing a tetracenequinone ring structure with a sugar attached by glycosidic linkage.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassAnthracyclines
Sub ClassNot Available
Direct ParentAnthracyclines
Alternative Parents
Substituents
  • Anthracyclinone-skeleton
  • Anthracycline
  • Aminoglycoside core
  • Tetracenequinone
  • Anthracene carboxylic acid
  • Anthracene carboxylic acid or derivatives
  • 1,4-anthraquinone
  • 9,10-anthraquinone
  • Anthracene
  • 1-naphthalenecarboxylic acid or derivatives
  • Disaccharide
  • Glycosyl compound
  • O-glycosyl compound
  • Tetralin
  • Aryl ketone
  • 1-hydroxy-4-unsubstituted benzenoid
  • Amino saccharide
  • 1-hydroxy-2-unsubstituted benzenoid
  • Benzenoid
  • Oxane
  • Tertiary alcohol
  • Methyl ester
  • Vinylogous acid
  • Secondary alcohol
  • Tertiary amine
  • Amino acid or derivatives
  • Tertiary aliphatic amine
  • Ketone
  • Cyclic ketone
  • Carboxylic acid ester
  • Polyol
  • Monocarboxylic acid or derivatives
  • Acetal
  • Carboxylic acid derivative
  • Oxacycle
  • Organoheterocyclic compound
  • Alcohol
  • Carbonyl group
  • Hydrocarbon derivative
  • Organic oxide
  • Organopnictogen compound
  • Organic oxygen compound
  • Organic nitrogen compound
  • Organonitrogen compound
  • Amine
  • Aldehyde
  • Organooxygen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Drug created on August 25, 2016 17:13 / Updated on August 25, 2016 17:19